| Project/Area Number |
12671232
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | KYUSHU UNIVERSITY |
|---|
Principal Investigator |
SADANAGA Noriaki Medical Institute of Bioregulation Kyushu Univ., Research Associate, 生体防御医学研究所, 助手 (20304826)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MORI Masaki Medical Institute of Bioregulation Kyushu Univ., Professor, 生体防御医学研究所, 教授 (70190999)
|
|---|
| Project Period (FY) |
2000 – 2001
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2001: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2000: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Keywords | cell cycle regulator / aurora 2 / colon cancer / gastric cancer / lymph node metastasis / aurora2 / 消化器癌 / 癌の悪性度 |
|---|
| Research Abstract |
Backgrounds: Aurora2 is a family of human serine/threonine kinases characterized as cell cycle regulators. In this study, we evaluated the expression of aurora 2 mRNA in gastro-intestinal carcinoma and the correlation between overexpression and clinico-pathological factors. Material and methods: We studied the 201 Japanese patients with carcinoma of gastrointestinal tract, including 53 esophageal cancer, 72 gastric cancer and 76 colorectal cancer. The expression of aurora 2 was investigated by RT-PCR. Results: Aurora 2 mRNA was expressed in 27 of 53 (51%) esophageal cancer, 38 of 72 (53%) gastric cancer and 36 of 76 (46%) colorectal cancer. The relations between the aurora2 expression and the clinicopathological factors was examined. In gastric carcinoma, lymph node metastasis was shown in 27 of 38 (71%) cases with aurora2 expression positive group, more frequent than those with negative expression (p<0.01). In colon carcinoma, lymph node metastasis was present in 23 of 36 (64%) cases with expression positive group and in 7 of 40 (18%) without, a statistically significant difference (p<0.01). There was lymphatic vessel invasion in 25 of 36 (69%) in the aurora2 expression positive group but in only 12 of 40 (30%) in the negative group (p<0.01). There was a significant differences between the two groups in Dukes classification (p<0.01). The overall 5-year survival rate for patients with aurora2 overexpression was lower than for patients without expression in colorectal cancer (92% vs. 64%, p<0.05). Conclusions: These results suggested that aurora2 expression was associated with tumor progression and patients survival and may be a new prognostic indicator for patients with colon carcinoma.
|
